Serum lipoprotein(a) and reclassification of coronary heart disease risk; application of prediction in a cross-sectional analysis of an ongoing Iranian cohort.
Coronary Heart Disease
Framingham Risk score
Integrated discrimination index
Lipoprotein(a)
Metabolic syndrome
Net reclassification improvement
Novel biomarker
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
02 Dec 2023
02 Dec 2023
Historique:
received:
28
06
2023
accepted:
25
11
2023
medline:
4
12
2023
pubmed:
3
12
2023
entrez:
2
12
2023
Statut:
epublish
Résumé
Recent studies have introduced elevated lipoprotein(a) (Lp(a)) as a risk factor for coronary heart disease (CHD). This study investigated whether the addition of Lp(a) as a novel biomarker to the Framingham Risk Score (FRS) model improves CHD risk prediction. The study included 1101 Iranian subjects (443 non-diabetic and 658 diabetic patients) who were followed for 10 years (2003-2013). Lp(a) levels and CHD events were recorded for each participant. The Net Reclassification Index (NRI) after adding Lp(a) to the FRS model was 19.57% and the discrimination slope was improved (0.160 vs. 0.173). The Akaike Information Criterion (AIC), a measure of model complexity, decreased significantly after adding Lp(a) to the FRS model (691.9 vs. 685.4, P value: 0.007). The study concluded that adding Lp(a) to the FRS model improves CHD risk prediction in an Iranian population without making the model too complex. This could help clinicians to better identify individuals who are at risk of developing CHD and to implement appropriate preventive measures.
Identifiants
pubmed: 38042772
doi: 10.1186/s12889-023-17332-w
pii: 10.1186/s12889-023-17332-w
pmc: PMC10693688
doi:
Substances chimiques
Lipoprotein(a)
0
LPA protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2402Informations de copyright
© 2023. The Author(s).
Références
Front Cardiovasc Med. 2023 Jan 12;9:1105413
pubmed: 36712246
Circulation. 2007 Feb 20;115(7):928-35
pubmed: 17309939
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
BMJ. 2007 Jul 21;335(7611):136
pubmed: 17615182
Eur Heart J. 2022 Oct 14;43(39):3925-3946
pubmed: 36036785
Int J Obes (Lond). 2008 May;32 Suppl 2:S17-20
pubmed: 18469835
Curr Atheroscler Rep. 2000 May;2(3):243-50
pubmed: 11122750
Lancet. 2012 Dec 15;380(9859):2224-60
pubmed: 23245609
Rev Esp Cardiol. 2011 Sep;64(9):788-94
pubmed: 21763052
BMC Public Health. 2021 Apr 24;21(1):790
pubmed: 33894756
J Am Coll Cardiol. 2013 Mar 19;61(11):1146-56
pubmed: 23375930
Stat Med. 2011 Jan 15;30(1):11-21
pubmed: 21204120
N Engl J Med. 2006 Dec 21;355(25):2631-9
pubmed: 17182988
Ann Intern Med. 2009 Oct 6;151(7):496-507
pubmed: 19805772
Diabetol Metab Syndr. 2010 Jun 08;2:36
pubmed: 20529329
Circulation. 1998 May 12;97(18):1837-47
pubmed: 9603539
J Clin Epidemiol. 1994 Dec;47(12):1353-64
pubmed: 7730844
Diabetes Care. 2013 Jan;36 Suppl 1:S11-66
pubmed: 23264422
J Am Coll Cardiol. 2014 Sep 2;64(9):851-60
pubmed: 25169167
Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12
pubmed: 17569110
J Am Coll Cardiol. 2018 Jul 17;72(3):287-296
pubmed: 30012322
Int J Epidemiol. 1985 Mar;14(1):32-8
pubmed: 3872850
Am J Med. 2012 Jul;125(7):695-703.e1
pubmed: 22727237
JAMA. 2012 Aug 22;308(8):788-95
pubmed: 22910756
Cochrane Database Syst Rev. 2011 Jan 19;(1):CD001561
pubmed: 21249647
Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e48-e60
pubmed: 34647487
J Clin Pathol. 2000 Jul;53(7):487-96
pubmed: 10961170